Lv2
130 积分 2023-12-07 加入
Sacituzumab Govitecan in Patients with Relapsed/Refractory Advanced Head and Neck Squamous Cell Carcinoma: Results from the Phase II TROPiCS-03 Basket Study
1个月前
已完结
The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis
1个月前
已完结
Multisystem immune-related adverse events during combined ipilimumab-nivolumab with subsequent disease progression: a case report
6个月前
已完结
Multisystem immune-related adverse reactions with immune checkpoint inhibitors
6个月前
已关闭
Anti-PD-1 and Regorafenib Induce Severe Multisystem Adverse Events in Microsatellite Stability Metastatic Colorectal Cancer: A Case Report
6个月前
已完结
Primary Biliary Cirrhosis and Granulomatous Hepatitis After Immune Checkpoint Blockade in Patients With Metastatic Melanoma: Report of 2 Cases and Literature Discussion
6个月前
已完结
Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer
6个月前
已完结
Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort study
8个月前
已完结
Network pharmacology, molecular docking and experimental study of CEP in nasopharyngeal carcinoma
8个月前
已完结
Delineation of the primary tumour Clinical Target Volumes (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG Oncology, PHNS, SBRT, SOMERA, SRO, SSHNO, TROG consensus guidelines
9个月前
已完结
皖公网安备34019202002308
